Arshadi Arash Keshavarzi, Salem Milad, Karner Heather, Garcia Kristle, Arab Abolfazl, Yuan Jiann Shiun, Goodarzi Hani
bioRxiv. 2023 Jan 16:2023.01.13.524005. doi: 10.1101/2023.01.13.524005.
MicroRNAs are recognized as key drivers in many cancers, but targeting them with small molecules remains a challenge. We present RiboStrike, a deep learning framework that identifies small molecules against specific microRNAs. To demonstrate its capabilities, we applied it to microRNA-21 (miR-21), a known driver of breast cancer. To ensure the selected molecules only targeted miR-21 and not other microRNAs, we also performed a counter-screen against DICER, an enzyme involved in microRNA biogenesis. Additionally, we used auxiliary models to evaluate toxicity and select the best candidates. Using datasets from various sources, we screened a pool of nine million molecules and identified eight, three of which showed anti-miR-21 activity in both reporter assays and RNA sequencing experiments. One of these was also tested in mouse models of breast cancer, resulting in a significant reduction of lung metastases. These results demonstrate RiboStrike’s ability to effectively screen for microRNA-targeting compounds in cancer.
微小RNA被认为是许多癌症的关键驱动因素,但用小分子靶向它们仍然是一项挑战。我们提出了RiboStrike,这是一个深度学习框架,可识别针对特定微小RNA的小分子。为了证明其能力,我们将其应用于微小RNA-21(miR-21),一种已知的乳腺癌驱动因素。为确保所选分子仅靶向miR-21而不靶向其他微小RNA,我们还针对参与微小RNA生物合成的酶DICER进行了反向筛选。此外,我们使用辅助模型评估毒性并选择最佳候选物。利用来自各种来源的数据集,我们筛选了900万个分子库,鉴定出8个,其中3个在报告基因检测和RNA测序实验中均显示出抗miR-21活性。其中一个还在乳腺癌小鼠模型中进行了测试,导致肺转移显著减少。这些结果证明了RiboStrike在癌症中有效筛选微小RNA靶向化合物的能力。